SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

                             Date of reported event:

                                  March 10, 2003



                              CITA BIOMEDICAL, INC.

             (Exact name of registrant as specified in its charter)



                   Delaware                           93-0962072

       (State or other jurisdiction of      (I.R.S. Employer Identification No.)
        incorporation or organization)



             9025 Wilshire Blvd. Suite 301, Beverly Hills, CA 90211

               (Address of principal executive offices) (Zip code)

                                 (310) 550-4971

              (Registrant's telephone number, including area code)

              (Former name, former address and former fiscal year,
                         if changed since last report.)



<PAGE>




ITEM 5. OTHER EVENTS.

CITA Biomedical,  Inc. ("CITA" "Company") has entered into a financing Agreement
("Agreement")  with  Reserva,  LLC that  provides the Company with three hundred
thousand dollars  ($300,000).  The Agreement  consists of a Security  Agreement,
Promissory  Note,  and  Guaranty  (attached  hereto as exhibits to this 8K). The
aforementioned  exhibits  explain  in detail  the terms and  conditions  of this
financing.  The Company plans to use this money for continuing operations and to
pursue strategic alliances to drive more patient volume to its treatment centers
in order to generate  enough cash to repay this debt  obligation.  In  addition,
CITA plans to have many discussions  over the next 90 days on contingency  plans
that will  enable the  Company to move  forward  and meet its debt  obligations.
However,  the Company can make no assurances this money will provide  sufficient
working capital to achieve breakeven from a cash flow perspective.

Further, if the Company is unsuccessful in utilizing this additional capital to
drive more patient volume to its treatment centers, and as a result, is in
default with the repayment terms in the Agreement, the Company will forfeit its
rights in all intellectual property owned by the Company. However, upon the
event of default, the Company would receive a three percent (3%) equity position
in any future Reserva, LLC entity or associated entity that will own the assets
pledged under the terms of the Agreement.

This release contains projections and other forward-looking statements regarding
future events and the future financial performance of CITA that involve risks
and uncertainties. Readers are cautioned that these forward-looking statements
are only predictions and may differ materially from actual future events or
results. Readers are referred to the documents filed by CITA with the SEC,
specifically the most recent reports on Form 10-KSB and 10-QSB, each as it may
be amended from time to time, which identify important risk factors that could
cause actual results to differ from those contained in the forward-looking
statements. The financial information contained in this release should be read
in conjunction with the consolidated financial statements and notes thereto
included in CITA's most recent reports on Form 10-KSB and Form 10-QSB, each as
it may be amended from time to time. CITA's results of operations for the three
and nine months ended September 30, 2002 are not necessarily indicative of
CITA's operating results for future periods.



ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.


FINANCIAL STATEMENTS:

None

PRO FORMA FINANCIAL INFORMATION

None

EXHIBITS

10.3     Security Agreement

10.4     Promissory Note

10.5     Guaranty



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

CITA BIOMEDICAL, INC.

Dated: March 10, 2003

By: /s/ Joseph Dunn
End of Filing





                                       2
<PAGE>
[{"type": "8-K", "sequence": "1", "filename": "cita8k.txt", "description": "CITA 8K", "secsgml_size_bytes": 4230}]
{"company-data": {"conformed-name": "CITA BIOMEDICAL INC", "cik": "0000700890", "assigned-sic": "8090", "irs-number": "930962072", "state-of-incorporation": "CO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-10965", "film-number": "03597929"}, "business-address": {"street1": "9025 WILSHIRE BLVD", "street2": "SUITE 301", "city": "BEVERLY HILLS", "state": "CA", "zip": "90211", "phone": "7196335301"}, "mail-address": {"street1": "9025 WILSHIRE BLVD", "street2": "SUITE 301", "city": "BEVERLY HILLS", "state": "CA", "zip": "90211"}, "former-company": [{"former-conformed-name": "BLUE GRASS BREEDERS INC", "date-changed": "19930701"}, {"former-conformed-name": "SOUTHWESTERN ENVIRONMENTAL CORP", "date-changed": "19930719"}]}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

                             Date of reported event:

                                  March 10, 2003

                              CITA BIOMEDICAL, INC.

             (Exact name of registrant as specified in its charter)

                   Delaware                           93-0962072

       (State or other jurisdiction of      (I.R.S. Employer Identification No.)
        incorporation or organization)

             9025 Wilshire Blvd. Suite 301, Beverly Hills, CA 90211

               (Address of principal executive offices) (Zip code)

                                 (310) 550-4971

              (Registrant's telephone number, including area code)

              (Former name, former address and former fiscal year,
                         if changed since last report.)
ITEM 5. OTHER EVENTS.

CITA Biomedical,  Inc. ("CITA" "Company") has entered into a financing Agreement
("Agreement")  with  Reserva,  LLC that  provides the Company with three hundred
thousand dollars  ($300,000).  The Agreement  consists of a Security  Agreement,
Promissory  Note,  and  Guaranty  (attached  hereto as exhibits to this 8K). The
aforementioned  exhibits  explain  in detail  the terms and  conditions  of this
financing.  The Company plans to use this money for continuing operations and to
pursue strategic alliances to drive more patient volume to its treatment centers
in order to generate  enough cash to repay this debt  obligation.  In  addition,
CITA plans to have many discussions  over the next 90 days on contingency  plans
that will  enable the  Company to move  forward  and meet its debt  obligations.
However,  the Company can make no assurances this money will provide  sufficient
working capital to achieve breakeven from a cash flow perspective.

Further, if the Company is unsuccessful in utilizing this additional capital to
drive more patient volume to its treatment centers, and as a result, is in
default with the repayment terms in the Agreement, the Company will forfeit its
rights in all intellectual property owned by the Company. However, upon the
event of default, the Company would receive a three percent (3%) equity position
in any future Reserva, LLC entity or associated entity that will own the assets
pledged under the terms of the Agreement.

This release contains projections and other forward-looking statements regarding
future events and the future financial performance of CITA that involve risks
and uncertainties. Readers are cautioned that these forward-looking statements
are only predictions and may differ materially from actual future events or
results. Readers are referred to the documents filed by CITA with the SEC,
specifically the most recent reports on Form 10-KSB and 10-QSB, each as it may
be amended from time to time, which identify important risk factors that could
cause actual results to differ from those contained in the forward-looking
statements. The financial information contained in this release should be read
in conjunction with the consolidated financial statements and notes thereto
included in CITA's most recent reports on Form 10-KSB and Form 10-QSB, each as
it may be amended from time to time. CITA's results of operations for the three
and nine months ended September 30, 2002 are not necessarily indicative of
CITA's operating results for future periods.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

FINANCIAL STATEMENTS:

None

PRO FORMA FINANCIAL INFORMATION

None

EXHIBITS

10.3     Security Agreement

10.4     Promissory Note

10.5     Guaranty

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

CITA BIOMEDICAL, INC.

Dated: March 10, 2003

By: /s/ Joseph Dunn
End of Filing

                                       2